Contact    |    Site Map    |    Careers

News & Publications

Acetylon Pharmaceuticals to Present Data Supporting ACY-1215 in Multiple Myeloma and Lymphoma at Upcoming Hematology Conferences


BOSTON, Mass. – June 13, 2013 – Acetylon Pharmaceuticals, Inc., the leader in development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that it will present preclinical and clinical data for the Company’s lead candidate, ACY-1215, at upcoming international hematology conferences. ACY-1215 is a selective HDAC6 inhibitor currently being evaluated in a Phase 1b clinical trial in combination with the best-in-class drug Revlimid® (lenalidomide, Celgene) and a Phase 1/2 clinical trial in combination with the first-in-class drug Velcade® (bortezomib, Takeda Millennium), for the treatment of relapsed or refractory multiple myeloma. Acetylon is also investigating ACY-1215 for the treatment of lymphoma in preclinical studies.

A poster presentation at the 18th Congress of the European Hematology Association in Stockholm, Sweden, on Saturday, June 15th, 2013, will provide updated safety and disease activity results from the two ongoing clinical trials of ACY-1215 in patients with relapsed or refractory multiple myeloma, including substantial disease response and favorable tolerability to treatment with ACY-1215, in combination with Velcade or Revlimid, plus low dose dexamethasone.

An oral presentation at the 12th International Conference on Malignant Lymphoma in Lugano, Switzerland, on Wednesday, June 19th, 2013, will highlight preclinical studies of ACY-1215 conducted by collaborators at Columbia University for the treatment of non-Hodgkins B-cell and T-cell lymphoma, in combination with Velcade.

The details of the upcoming presentations are as follow:

18th Congress of the European Hematology Association

Date: Saturday, June 15, 2013

Time: 5:45-7:00 pm CEST

Location: Poster Hall

Session: Multiple Myeloma – Translational and Clinical Studies 2

Abstract #: P765

Title: New Drug Partner for Combination Therapy in Multiple Myeloma (MM): Development of ACY-1215, a Selective Histone Deacetylase 6 Inhibitor Alone and in Combination with Bortezomib or Lenalidomide

Presenting Author: Catherine A. Wheeler, MD, Acetylon Pharmaceuticals

Author Affiliations: Massachusetts General Hospital, University of Pennsylvania, University of North Carolina at Chapel Hill, University of Washington Fred Hutchinson Cancer Research Center, Medical College of Wisconsin, Sarah Cannon Research Institute, Mount Sinai Hospital, University of Texas MD Anderson Cancer Institute, Emory University Winship Cancer Institute and Acetylon Pharmaceuticals

12th International Conference on Malignant Lymphoma

Date: Wednesday, June 19, 2013

Time:  5:45pm CEST

Location: Palazzo dei Congressi, Room C

Session: Preclinical Assays

Title: Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor, ACY-1215 (ACY), and Bortezomib (Bor), Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Presenting Author: Jennifer E. Amengual, MD, Columbia University Medical Center

Author Affiliations: Columbia University Medical Center and Acetylon Pharmaceuticals

About ACY-1215

 Blood cancers such as multiple myeloma and lymphoma are characterized by successive genetic mutations resulting in rapid cell proliferation and excess production of intracellular proteins. ACY-1215 selectively inhibits the intracellular enzyme HDAC6, leading to inactivation of the "aggresome" pathway for degradation of damaged proteins. The resultant accumulation of excess waste protein in malignant cells triggers programmed cell death, called "apoptosis," with little or no effect on normal cells. Currently available HDAC drugs non-selectively target multiple HDAC enzymes including those of Class I, resulting in dysregulated expression of numerous genes in normal cells as well as cancer cells. Side effects commonly associated with non-selective epigenetic HDAC drugs include gastrointestinal dysfunction, lowered blood platelet levels and risk of hemorrhage, and profound fatigue as well as potential for severe cardiac complications. Selective inhibition of HDAC6 is expected to reduce or eliminate these often-severe side effects associated with non-selective HDAC inhibition and may enable the development of optimized treatment regimens including maximally effective combination drug therapies.

About Acetylon Pharmaceuticals, Inc.

 Acetylon Pharmaceuticals Inc. is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhanced therapeutic outcome of cancer and other critical unmet medical needs. The Company’s epigenetic drug discovery platform has initially yielded a proprietary library of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases, including cancer, sickle cell disease, beta-thalassemia, and autoimmune and neurologic diseases. Acetylon’s lead drug candidate, ACY-1215, is a selective HDAC6 inhibitor in clinical development for the treatment of multiple myeloma. 


Walter C. Ogier
President and Chief Executive Officer
(617) 435-2664

MacDougall Biomedical Communications

Kari Watson
(781) 235-3060

Michelle Avery
(781) 235-3060